Case report {#S0001}
===========

A 65-year-old woman with a medical history of heart disease was urgently admitted to the department due to sudden cardiac arrest of ventricular fibrillation. The patient had undergone cardiac surgery in the past (in 2004) because of complex mitral valve disease with predominance of regurgitation. The procedure of prosthetic mitral valve implantation (SJM-29 valve) was accompanied by a prosthetic aortic valve implantation (SJM-21 valve) due to moderate stenosis of the valve and tricuspid valvuloplasty due to significant regurgitation of the valve. Valvular dysfunctions did not coexist with coronary artery disease. Left ventricular systolic function before the procedure was depressed (ejection fraction 35%). Because of symptomatic bradycardia accompanying persistent atrial fibrillation the patient also underwent a VVI type pacemaker implantation (in 2004). The patient has also had some oncological history. She underwent left side nephrectomy and extirpation of the uterus with appendages due to ovarian and renal cancer (in 2010). In November 2011 the patient suffered from low-risk pulmonary embolism. Difficulties with pharmacological control of the heart rhythm with concomitant European Heart Rhythm Assiociation (EHRA) class IV symptoms were the reasons for performance of a successful conductance modification through the atrioventricular node by means of RF ablation done in September 2011. After the procedure the heart rhythm remained at about 70 bmp with ventricular pacing comprising 40-50% of beats. Because of this fact as well as significantly depressed left ventricular systolic function with ejection fraction of 25% the patient was also qualified for resynchronization therapy by an upgrade of the existing device. Coronary angiography performed during this hospitalization did not show atherosclerotic changes in coronary arteries. Due to a previous episode of pulmonary embolism and other medical history, an oncological examination was ordered before the introduction of resynchronization therapy. It did not demonstrate any signs of cancer recurrence or dissemination. The presence of prosthetic heart valves, a previous episode of pulmonary embolism and atrial fibrillation were the reasons for chronic anticoagula-tion with vitamin K antagonists. The therapy was difficult because of labile international normalized ratio (INR) values. An immeasurable INR value without signs of clinically overt bleeding was observed in December 2011 during the patient\'s hospitalization on the internal ward due to stomach pain and loss of appetite. At that time she was treated with intravenous administration of 10 mg of vitamin K. The abrupt drop of prothrombin level was probably caused by depressed liver synthesis of coagulation factors and decreased absorption of vitamin K caused by retention of blood in the organs of the abdominal cavity secondary to decompensating heart failure. After the pharmacological intervention INR values decreased to 1.18 and were the starting point of approximately 2 weeks of transient (warfarin) resistance.

In the present case the diagnosis of ventricular fibrillation was made by an ambulance crew at the patient\'s home. Ventricular fibrillation, successfully terminated by defibrillation, reoccurred several times. Electrocardiogram registered after defibrillations showed signs of myocardial infarction within the paced rhythm ([Figure 1](#F0001){ref-type="fig"}). The patient was intubated and mechanically ventilated. After reaching the hospital she was transferred from the ER directly to the catheterization laboratory.

![Electrocardiogram performed on admission](PWKI-9-20459-g001){#F0001}

The patient had a paced rhythm of 70 bmp, and arterial blood pressure of 100/60 mm Hg after infusion of catecholamines (dopamine at 8 µg/kg/min). Laboratory examinations demonstrated leukocytosis (12.87 thousand/µl), slight normocytic anemia (hemoglobin 11.6 g/dl), increased levels of D-dimers (9.38 µg/ml), creatinine (1.57 mg/dl), potassium (5.84 mmol/l) and troponin I (0.033 ng/ml). International normalized ratio was 2.18.

Coronary angiography showed the occluded large circumflex artery (Cx) with lack of significant lesions in the other coronary arteries. Angiography suggested the presence of Cx occlusion caused by arterial thrombus ([Figure 2](#F0002){ref-type="fig"}). This suspicion led to the use of aspiration thrombectomy as the first choice (Export Catheter 6 F). After three passages with the aspiration catheter, its retraction to the guiding catheter under constant vacuum and aspiration of blood from the guiding catheter, several macroscopically visible, large fragments of red thrombus were demonstrated ([Figure 3](#F0003){ref-type="fig"}). Contrast administration to the left coronary artery showed total recanalization of the circumflex artery with normal flow to the peripheries of the vessel. At the same time there were no atherosclerotic changes at the site of previous artery occlusion (Cx/Mo1 bifurcation). Intravascular ultrasound (IVUS) of the circumflex and marginal arteries was done to exclude dissection as a cause of acute arterial thrombosis. The images from IVUS confirmed the presence of insignificant, stable atherosclerotic lesions without damage to the vascular wall ([Figure 4](#F0004){ref-type="fig"}). No signs of residual peri-mural thrombus were observed. After successful opening of the artery the patient\'s condition gradually improved, and arterial blood pressure rose to 120/70 mm Hg. The patient was transferred to the intensive care unit. Transesophageal echocardiography did not reveal the presence of embolic material on the heart valves or in the left atrial appendage. However, a spontaneous echo contrast of blood in the heart chambers was observed. Because of stable ECG catecholamine infusion was reduced on the next day and then completely stopped together with sedation discontinuation. Subsequently the patient was extubated. There were no neurological deficits observed as the patient regained consciousness. She remained in a stable hemodynamic condition.

![Angiogram of left coronary artery (the arrow shows occlusion of LCx)](PWKI-9-20459-g002){#F0002}

![The thrombus aspirated from LCx](PWKI-9-20459-g003){#F0003}

![Angiogram and intracoronary ultrasound of left coronary artery after thrombectomy](PWKI-9-20459-g004){#F0004}

Due to persistence of class III/IV symptoms of heart failure despite optimal pharmacotherapy, the presence of signs of electric dyssynchrony (QRS 140 ms) and normal results of oncological examination the patient was qualified for cardiac resynchronization therapy.

Discussion {#S0002}
==========

Despite the lack of thrombotic material on prosthetic valves or in the left atrium on transoesophageal echocardiography we decided that the most likely reason for circumflex artery occlusion was embolic material originating from the left heart chambers. Inadequate control of INR and its non-therapeutic values after the use of intravenous vitamin K might have been a cause of thrombotic material generation. Medical documentation delivered to the hospital showed INR values between 1.18 and 1.12 during the period of 10 days preceding the current hospitalization. Embolic aetiology of the presented cardiovascular incident was also suggested by the lack of atherosclerotic changes in coronary arteries including particularly a lack of unstable plaque, dissection or peri-mural thrombus.

Ineffective antithrombotic therapy is an important therapeutic problem concerning up to 2/3 of patients requiring this type of treatment \[[@CIT0001]\]. International normalized ratio values in patients chronically treated with oral anticoagulants are outside the therapeutic range for 34-60% of the time \[[@CIT0002], [@CIT0003]\]. Vitamin K antagonists have a relatively narrow therapeutic window and their use is subject to obligatory and regular monitoring of coagulation parameters, which increases the costs of therapy and influences the patient\'s quality of life. These difficulties led to the search for more effective, safer and more predictable methods of thromboprophylaxis. This research resulted in development of 2 new groups of oral anticoagulant drugs having different mechanisms of action and not requiring anticoagulation effect monitoring, i.e. direct thrombin inhibitors (dabigatran and ximelagatran, which was withdrawn because of hepatotoxicity) and factor Xa inhibitors (rivaroxaban, apixaban, betrixaban). Dabigatran was shown to be effective in the prevention of ischaemic strokes in patients with atrial fibrillation (RE-LY study) \[[@CIT0004]\], in the prevention of primary deep venous thromboembolism (DVT) (RE-NOVATE, RE-NOVATE II) \[[@CIT0005], [@CIT0006]\], in the treatment of symptomatic DVT (RE-COVER, RE-COVER II) \[[@CIT0007]\] and in the prevention of secondary DVT (RE-MEDY, RE-SONATE) \[[@CIT0008]\]. Despite that, according to the most recent update \[[@CIT0009]\], the drug is not effective enough in patients with prosthetic heart valves (also in patients with renal or liver failure). Other drugs such as rivaroxaban are also not indicated as antithrombotic treatment in patients with prosthetic heart valves.

The present case is a dramatic illustration of difficulties related to antithrombotic treatment. It may be assumed that these types of therapeutic problems are partially iatrogenic. Vitamin K administration in case of oral anticoagulant overdosing may lead to long lasting resistance to vitamin K antagonists with its very serious consequences. Intravenous administration of vitamin K should be limited to patients with significant and life-threatening bleeding irrespectively of the INR values. In the present case the intervention could possibly have been limited to oral vitamin K supplementation at a lower dose and temporary withdrawal of the antithrombotic drug. However, given the frequency of emerging difficulties in maintaining the desired effects of antithrombotic treatment, it is particularly important to continue research on new drugs also in patients with prosthetic heart valves. The currently ongoing phase II clinical trial REALIGN assesses the efficacy of dabigatran in comparison to warfarin in patients with prosthetic mitral or aortic valve; the project should end in 2018.
